Fresolimumab is a human monoclonal antibody targeting transforming growth factor beta (TGF-_). Fresolimumab inhibits the activity of TGF-beta, which may result in the suppression of tumor cell growth, angiogenesis, and migration.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.